Abstract:Abstract INTRODUCTION Patients with inflammatory bowel disease (IBD) often experience symptoms such as abdominal pain, diarrhea, and bloody bowel movements. While these symptoms traditionally guided treatment, their predictive value for disease progression is limited. The latest STRIDE-II guidelines recommend a comprehensive IBD management approach, with an emphasis on short-term symptom relief, intermediate-term biomarker normalization, and long-term achievement of endoscopic remission. This treat-to-target strategy necessitates collaboration between physicians and patients. Our study aims to investigate the relationship between patient-reported outcomes and physician efforts to achieve mucosal healing (MH) using IBD QORUS patient and provider survey data. METHODS This was a multi-center prospective study that used patient and provider matched survey data from the Crohn’s & Colitis Foundation IBD QORUS program. Surveys completed between June 2021-October 2022 were analyzed. Univariate and multivariate analyses were performed to determine the relationship between severity of patient reported symptoms and frequency of MH assessment with modalities including endoscopy and fecal calprotectin, as well as to determine how symptoms and MH status influence treatment. RESULTS In total 5,460 paired patient and provider surveys (Crohn’s disease (CD), n=3,276; ulcerative colitis (UC), n=2,184) were included in the analysis. Demographic information including age, sex and steroid-free MH, as well as severity of patient-reported symptoms were similar between CD and UC patients (Table 1). Abdominal pain severity reported by both IBD populations significantly impacted plans for future endoscopy (CD, p=0.000019; UC, p=0.000055) but not for fecal calprotectin testing. Reported stool frequency in both IBD populations significantly impacted future endoscopy plans (CD, p=0.000001; UC, p=0.000001) and future fecal calprotectin testing (CD, p=0.000304; UC, p=0.000001). Reported blood in stool had no effect on MH assessment in CD patients whereas it significantly affected plans for endoscopy (p=0.000001) and fecal calprotectin testing (p=0.000001) in UC patients. Provider discussions regarding MH occurred with 82.4% of CD patients and 85.3% of UC patients, and treatment plans in those without steroid free MH were influenced by severity of symptoms (p=0.000001). DISCUSSION Patient reported symptoms influenced fecal calprotectin and endoscopy plans in both IBD groups. Similarly, severity of symptoms in those without steroid-free MH significantly affected treatment management. These findings suggest that target-based treatment for IBD is feasible in the clinical setting and holds the potential to enhance patient outcomes.

Factors Associated with Mucosal Healing in Patients with Ulcerative Colitis in Clinical Remission.

Lower ultra-short-term heart rate variability is a risk factor for worse mucosal healing in ulcerative colitis

Lower Ultra-Short-term Heart Rate Variability Can Predict Worse Mucosal Healing in Ulcerative Colitis.

22 Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-Based Inception Cohort Study from Six Countries in Asia

Histologic healing and clinical outcomes in ulcerative colitis

P577 Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

Predictive value of serum markers for mucosal healing in patients with inflammatory bowel disease

Mucosal gene transcription of ulcerative colitis in endoscopic remission

Mucosal cytokine expression associated with deep endoscopic mucosal healing in ulcerative colitis

Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis

P246 Histologic remission is an important therapeutic target in patients who achieve endoscopic remission of ulcerative colitis

Risk factors for clinical relapse in patients with ulcerative colitis who are in clinical remission but with endoscopic activity

Molecular Signature of Persistent Histological Inflammation in Ulcerative Colitis with Mucosal Healing

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors.

EXPLORING THE RELATIONSHIP BETWEEN PATIENT SYMPTOMS AND PROVIDER GOALS FOR MUCOSAL HEALING IN IBD: INSIGHTS FROM THE IBD QORUS SURVEY DATA

P231 Impact of the depth of mucosal healing on the burden of ulcerative colitis : a cross-sectional study

P1210 Gut microbiota profiling and disease course in patients with ulcerative colitis in clinical remission

Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights

Long-term outcomes and associated factors of Crohn's disease patients achieving transmural healing based on magnetic resonance enterography: a Chinese retrospective cohort study

Development and validation of a novel criterion of histologic healing in ulcerative colitis defined by inflammatory cell enumeration in lamina propria mucosa: A multicenter retrospective cohort in China

P254 Outcomes of endoscopic and histologic remission in ulcerative colitis under advanced therapy